Why some people try synthetic products to quit and why that is risky

Across several regions people seeking to stop or reduce opioid and stimulant use have turned to novel synthetic products, driven by limited access to formal treatment, online communities and the promise of a quick 'off‑ramp'. While these motivations are understandable, the chemistry of these products can be intentionally altered to evade law, which makes dose and effect difficult to predict. Consequently, people may be exposed to substances that are far more potent than expected.

United Nations monitoring and European drug agencies have documented synthetic opioids and stimulants appearing in atypical forms — vapes, adulterated tablets and plant products — and these presentations have been linked to unexpected overdoses and emergency admissions. Harm reduction research that surveyed users has shown not only recreational motives but also attempts to reduce or stop previous drug use, while reporting adverse effects and variable product composition.

Medical ethicists have noted that self-experimentation raises practical and moral questions, especially when it takes place outside medical supervision and when outcomes are publicised or emulated online; such activity can undermine public health efforts and place additional burdens on emergency services. If clinicians are consulted, safer tapering and medication‑assisted options can be arranged, with monitoring that reduces the chance of severe withdrawal or overdose.

Nevertheless, individuals who feel compelled to try new products should at minimum inform a health professional and carry naloxone where opioid exposure is possible. Moreover, community harm reduction services can offer drug checking, advice and referrals that lower risk. If formal treatment is not immediately available, peer support and supervised tapering can be safer than isolated self-detox; but the preferred route is clinician-led care.